| dc.contributor.author |
Finan, Ramzi |
|
| dc.contributor.author |
Dahdouh, Elias |
|
| dc.contributor.author |
Sabra, Mona |
|
| dc.contributor.author |
Zreik, Tony |
|
| dc.date.accessioned |
2015-10-07T08:40:07Z |
|
| dc.date.available |
2015-10-07T08:40:07Z |
|
| dc.date.copyright |
2005 |
|
| dc.date.issued |
2015-10-07 |
|
| dc.identifier.issn |
0301-2115 |
en_US |
| dc.identifier.uri |
http://hdl.handle.net/10725/2270 |
|
| dc.description.abstract |
Sibutramine hydrochloride monohydrate is an orally administered agent for the treatment of obesity. Chemically, the active ingredient is a racemic mixture of (+) and (−) enantiomers of cyclobutanemethanamine [1]. It produces its therapeutic effect by norepinephrine, serotonin, and dopamine reuptake inhibition, and it exerts its pharmacologic actions via two active metabolites M1 and M2 [1,2]. Menstrual irregularities along with elevation in blood pressure and heart rate have been reported with the use of sibutramine. |
|
| dc.language.iso |
en |
en_US |
| dc.title |
Sibutramine in pregnancy |
en_US |
| dc.type |
Article |
en_US |
| dc.description.version |
Published |
en_US |
| dc.author.school |
SOM |
en_US |
| dc.author.idnumber |
200802707 |
|
| dc.author.woa |
N/A |
en_US |
| dc.author.department |
N/A |
en_US |
| dc.description.embargo |
N/A |
en_US |
| dc.relation.journal |
European journal of obstetrics, gynecology, and reproductive biology |
en_US |
| dc.journal.volume |
122 |
en_US |
| dc.journal.issue |
2 |
en_US |
| dc.article.pages |
243-244 |
en_US |
| dc.identifier.doi |
http://dx.doi.org/10.1016/j.ejogrb.2005.02.016 |
|
| dc.identifier.ctation |
Ramzi, F., Elias, D., Mona, S., & Zreik, T. G. (2005). Sibutramine in pregnancy. European Journal of Obstetrics & Gynecology and Reproductive Biology, 122(2), 243-244. |
en_US |
| dc.author.email |
tgzreik@lau.edu.lb |
|